Phoenix Life Sciences International Limited (PLSI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Phoenix Life Sciences International Limited (PLSI) trades at $0.0001. Phoenix Life Sciences International Limited is a healthcare solutions company focused on research, program integration, and product manufacturing for various disorders. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for PLSI: PLSI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PLSI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PLSI: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Phoenix Life Sciences International Limited (PLSI) Healthcare & Pipeline Overview
Phoenix Life Sciences International Limited, operating in the healthcare sector, focuses on developing and manufacturing products targeting diabetes, pain, cancers, and other disorders. The company offers diverse delivery methods, including oral and topical applications, but faces challenges typical of small OTC-listed pharmaceutical companies.
What Is the Investment Thesis for PLSI?
Phoenix Life Sciences International Limited presents a high-risk, high-reward investment profile. The company's focus on developing treatments for a wide range of disorders, including diabetes, pain, and cancers, provides potential for significant growth if its research and product development efforts are successful. However, the company's small size, limited resources, and OTC listing introduce substantial risks. Key value drivers include successful clinical trials, regulatory approvals, and commercialization of its products. The company's beta of 204.07 indicates extremely high volatility relative to the market. Investors should carefully consider the risks associated with investing in small, OTC-listed companies in the pharmaceutical sector before making any investment decisions. The lack of a dividend further reduces its appeal to income-focused investors.
Based on FMP financials and quantitative analysis
PLSI Key Highlights
Phoenix Life Sciences International Limited operates in the healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry.
- The company focuses on research, program integration, and manufacturing of products targeting diabetes, pain, cancers, and various other disorders.
- Phoenix Life Sciences International Limited offers diverse delivery methods for its products, including oral capsules, dissolvable strips, and topical creams.
- The company has a market capitalization of $0.00B, indicating its small size and early stage of development.
- Phoenix Life Sciences International Limited trades on the OTC market, which typically involves higher risks and lower liquidity compared to major exchanges.
Who Are PLSI's Competitors?
PLSI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PLSI's Key Strengths?
Diverse product offerings targeting multiple medical conditions.
- Variety of drug delivery methods.
- Focus on research and development.
- Potential for growth in niche markets.
What Are PLSI's Weaknesses?
Small size and limited resources.
- OTC listing with lower liquidity.
- Dependence on successful product development.
- Limited market presence and brand recognition.
What Could Drive PLSI Stock Higher?
Successful completion of clinical trials for key products.
- Regulatory approvals from the FDA or other international agencies.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new geographic markets.
- Development of novel drug delivery systems.
What Are the Key Risks for PLSI?
Financial-distress signal — its Altman Z-Score of -4.08 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-71.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trials or regulatory setbacks.
- Intense competition from larger pharmaceutical companies.
- Product liability claims or recalls.
- Limited financial resources and dependence on external funding.
- OTC listing with lower liquidity and higher volatility.
What Are the Growth Opportunities for PLSI?
- Expansion into New Therapeutic Areas: Phoenix Life Sciences International Limited has the opportunity to expand its product pipeline by targeting additional therapeutic areas with unmet medical needs. By investing in research and development in these areas, the company could diversify its revenue streams and reduce its reliance on its current product offerings. This expansion could begin within the next 2-3 years as new research initiatives mature.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Phoenix Life Sciences International Limited with access to additional resources, expertise, and distribution channels. Collaborations can accelerate product development timelines and reduce the financial burden of clinical trials and regulatory approvals. The pharmaceutical industry is rife with collaborations, and this could be a viable path within the next 1-2 years.
- Geographic Expansion into International Markets: Expanding its geographic footprint beyond the United States could unlock new growth opportunities for Phoenix Life Sciences International Limited. Emerging markets, such as Asia and Latin America, offer significant potential due to their growing populations and increasing healthcare spending. However, navigating regulatory requirements and establishing distribution networks in these markets will be critical. This expansion could occur over the next 3-5 years.
- Development of Novel Drug Delivery Systems: Investing in the development of innovative drug delivery systems could provide Phoenix Life Sciences International Limited with a competitive advantage. Novel delivery methods, such as targeted drug delivery and sustained-release formulations, can improve drug efficacy, reduce side effects, and enhance patient compliance. The market for advanced drug delivery systems is growing rapidly, and this could be a key differentiator within the next 2-4 years.
- Capitalizing on the Growing Market for Personalized Medicine: As the field of personalized medicine continues to advance, Phoenix Life Sciences International Limited could focus on developing targeted therapies based on individual patient characteristics. This approach requires investment in diagnostics and data analytics capabilities but offers the potential for more effective treatments and improved patient outcomes. The personalized medicine market is expected to expand significantly over the next 5 years.
What Are PLSI's Competitive Advantages?
- Proprietary formulations and drug delivery systems.
- Focus on niche markets with unmet medical needs.
- Established relationships with healthcare providers.
- Intellectual property protection through patents and trademarks.
What Does PLSI Do?
Phoenix Life Sciences International Limited, established in 2009 and headquartered in Las Vegas, Nevada, operates as a healthcare solutions company with a focus on researching, integrating programs, and manufacturing products aimed at treating a range of conditions. These include diabetes, pain, cancers, psychological disorders, gastrointestinal issues, autoimmune diseases, neurological conditions, and sleep disorders. The company offers a variety of delivery methods for its products, such as oral soft gel capsules, thin film dissolvable strips, transdermal patches, sublingual oral sprays, suppositories, and topical creams. Originally incorporated as Stem Bioscience, Inc., the company rebranded to Phoenix Life Sciences International Limited in May 2018, signaling a strategic shift in its business focus. With a small team of 5 employees, Phoenix Life Sciences International Limited aims to serve both the United States and international markets, positioning itself within the specialty and generic drug manufacturing segment of the healthcare industry. The company's strategy involves developing and commercializing healthcare solutions for a diverse set of medical conditions.
What Products and Services Does PLSI Offer?
- Researches and develops healthcare solutions.
- Integrates programs targeting various medical conditions.
- Manufactures products for diabetes, pain, and cancers.
- Addresses psychological, gastrointestinal, and autoimmune disorders.
- Develops treatments for neurological and sleep disorders.
- Offers oral soft gel capsules and thin film dissolvable strips.
- Provides transdermal patches and sublingual oral sprays.
- Creates suppositories and topical creams.
How Does PLSI Make Money?
- Develops and manufactures pharmaceutical products.
- Sells products through various distribution channels.
- Generates revenue from product sales.
- Focuses on niche markets within the healthcare industry.
What Industry Does PLSI Operate In?
Phoenix Life Sciences International Limited operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The market is driven by an aging population, increasing prevalence of chronic diseases, and the rising demand for affordable healthcare solutions. Companies in this sector face challenges such as high research and development costs, stringent regulatory requirements, and the need to navigate complex intellectual property landscapes.
Who Are PLSI's Key Customers?
- Patients seeking treatment for diabetes, pain, and cancers.
- Individuals with psychological, gastrointestinal, and autoimmune disorders.
- People suffering from neurological and sleep disorders.
- Healthcare providers prescribing or recommending the company's products.
Company Profile
Phoenix Life Sciences International Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Willis Victory. PLSI has traded publicly since 2011.
Key Financial Metrics
Return on equity for Phoenix Life Sciences International Limited stands at -71.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.3%, showing how much profit it generates from its asset base. A current ratio of 1.76 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Phoenix Life Sciences International Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.08 places it in the distress zone, a signal of elevated financial risk.
PLSI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diverse product offerings targeting multiple medical conditions.
- Variety of drug delivery methods.
- Focus on research and development.
- Potential for growth in niche markets.
Bear Case
- Small size and limited resources.
- OTC listing with lower liquidity.
- Dependence on successful product development.
- Limited market presence and brand recognition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PLSI Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Aug 16, 2019
PLSI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PLSI.
Price Targets
Wall Street price target analysis for PLSI.
PLSI MoonshotScore
What does this score mean?
The MoonshotScore rates PLSI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Willis Victory
CEO
Willis Victory is the CEO of Phoenix Life Sciences International Limited, leading a small team of 5 employees. Information about his prior experience and educational background is not available. As the CEO, he is responsible for the overall strategic direction and operational management of the company, including research and development, product manufacturing, and sales and marketing efforts. His leadership is critical to the company's success in the competitive healthcare solutions market.
Track Record: Due to limited information, Willis Victory's specific achievements and strategic decisions at Phoenix Life Sciences International Limited are not available. The company's current market capitalization of $0.00B and OTC listing suggest that it is still in an early stage of development. His track record will be determined by his ability to drive revenue growth, secure regulatory approvals, and establish a sustainable business model.
PLSI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading in these securities is often characterized by high risk and low liquidity. Investing in OTC Other securities requires a high degree of due diligence and risk tolerance due to the potential for fraud, manipulation, and lack of transparency. These companies often do not meet minimum financial standards.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low liquidity and wide bid-ask spreads.
- Potential for fraud and manipulation.
- Higher risk of business failure.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Understand the risks associated with investing in OTC securities.
- Consult with a qualified financial advisor.
- Check for any legal or regulatory issues.
- Company has been in operation since 2009.
- Focus on research and development in the healthcare sector.
- Offers a range of products targeting various medical conditions.
- Presence of a CEO and management team.
- Company changed its name to Phoenix Life Sciences International Limited in May 2018, signaling a strategic shift.
Common Questions About PLSI (Healthcare)
What does Phoenix Life Sciences International Limited do?
Phoenix Life Sciences International Limited is a healthcare solutions company that focuses on researching, developing, and manufacturing products targeting a variety of medical conditions. These include diabetes, pain, cancers, psychological disorders, gastrointestinal issues, autoimmune diseases, neurological conditions, and sleep disorders.
What do analysts say about PLSI stock?
As of March 18, 2026, there is no available analyst coverage or consensus estimates for Phoenix Life Sciences International Limited (PLSI). This is likely due to the company's small size, OTC listing, and limited financial disclosure. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are not meaningful due to the company's current financial performance.
What are the main risks for PLSI?
Phoenix Life Sciences International Limited faces several significant risks. As a small, OTC-listed company, it has limited financial resources and faces intense competition from larger pharmaceutical companies. The company's success depends on the successful completion of clinical trials and regulatory approvals, which are inherently uncertain. There is also the risk of product liability claims and recalls.
What are the key factors to evaluate for PLSI?
Evaluate PLSI on fundamentals, analyst consensus, and risk factors. Phoenix Life Sciences International Limited presents a high-risk, high-reward investment profile. Not financial advice.
How frequently does PLSI data refresh on this page?
PLSI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PLSI's recent stock price performance?
Phoenix Life Sciences International Limited (PLSI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product offerings targeting multiple medical conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PLSI overvalued or undervalued right now?
Phoenix Life Sciences International Limited (PLSI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PLSI before investing?
Before investing in Phoenix Life Sciences International Limited (PLSI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing introduces higher risks and uncertainties.
- AI analysis pending for PLSI.